Pentapeptide cRGDfK-Surface Engineered Nanostructured Lipid Carriers as an Efficient Tool for Targeted Delivery of Tyrosine Kinase Inhibitor for Battling Hepatocellular Carcinoma

References

• Llovet JM, Kelley RK, Villanueva A., et al. Hepatocellular carcinoma. Nat Rev Dis Prim. 2021;7(1):6. doi:10.1038/s41572-020-00240-3
   PubMed Web of Science ®Google Scholar
• Zhang H, Zhang W, Jiang L, et al. Recent advances in systemic therapy for hepatocellular carcinoma. Biomar Res. 2022;10(1):3. doi:10.1186/s40364-021-00350-4
   PubMed Web of Science ®Google Scholar
• Zhu J, Huang Y, Zhang J, et al. Formulation, preparation and evaluation of nanostructured lipid carrier containing naringin and coix seed oil for anti-tumor application based on “unification of medicines and excipients”. Drug Des Devel Ther. 2020;14:1481–1491. doi:10.2147/DDDT.S236997
   PubMed Web of Science ®Google Scholar
• Elsegood CL, Tirnitz‐Parker JE, Olynyk JK, et al. Immune checkpoint inhibition: prospects for prevention and therapy of hepatocellular carcinoma. Clin Trans Immunol. 2017;6(11):e161. doi:10.1038/cti.2017.47
   PubMedGoogle Scholar
• Foroughi-Nia B, Barar J, Memar MY, et al. Progresses in polymeric nanoparticles for delivery of tyrosine kinase inhibitors. Life Sci. 2021;278:119642. doi:10.1016/j.lfs.2021.119642
   PubMed Web of Science ®Google Scholar
• Höpfner M, Sutter AP, Huether A, et al. Targeting the epidermal growth factor receptor by gefitinib for treatment of hepatocellular carcinoma. J Hepatol. 2004;41(6):1008–1016. doi:10.1016/j.jhep.2004.08.024
   PubMed Web of Science ®Google Scholar
• Shi Y, Su C, Cui W, et al. Gefitinib loaded folate decorated bovine serum albumin conjugated carboxymethyl-beta-cyclodextrin nanoparticles enhance drug delivery and attenuate autophagy in folate receptor-positive cancer cells. J Nanobiotechnology. 2014;12(1):43. doi:10.1186/s12951-014-0043-7
   PubMedGoogle Scholar
• Sordella R, Bell DW, Haber DA, et al. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science. 2004;305(5687):1163–1167. doi:10.1126/science.1101637
   PubMed Web of Science ®Google Scholar
• Soni K, Rizwanullah M, Kohli K. Development and optimization of sulforaphane-loaded nanostructured lipid carriers by the Box-Behnken design for improved oral efficacy against cancer: in vitro, ex vivo and in vivo assessments. Artif Cells, Nanomed Biotechnol. 2018;46(sup1):15–31. doi:10.1080/21691401.2017.1408124
   PubMed Web of Science ®Google Scholar
• Deepak P, Siddalingam R, Kumar P, et al. Gene based nanocarrier delivery for the treatment of hepatocellular carcinoma. J Drug Deliv Sci Technol. 2020;59:101837. doi:10.1016/j.jddst.2020.101837
   Web of Science ®Google Scholar
• Pandey P, Gupta PC, Yadav S. Solid lipid nanoparticle: a potential approach in drug delivery system. Eur J Pharm Med Res. 2018;5(9):225–236.
   Google Scholar
• Rajinikanth PS, Chellian J Development and evaluation of nanostructured lipid carrier-based hydrogel for topical delivery of 5-fluorouracil. Int J Nanomedicine. 2016 Oct 5:5067–5077.
   Google Scholar
• Mahmoud K, Swidan S, El-Nabarawi M, et al. Lipid based nanoparticles as a novel treatment modality for hepatocellular carcinoma: a comprehensive review on targeting and recent advances. J Nanobiotechnology. 2022;20(1):109. doi:10.1186/s12951-022-01309-9
   PubMed Web of Science ®Google Scholar
• Zhu X, Deng X, Lu C, et al. SPIO-loaded nanostructured lipid carriers as liver-targeted molecular T2-weighted MRI contrast agent. Quant Imaging Med Surg. 2018;8(8):770–780. doi:10.21037/qims.2018.09.03
   PubMed Web of Science ®Google Scholar
• Pandey P, Kumar Arya D, Kumar Ramar M, et al. Engineered nanomaterials as an effective tool for HER2+ breast cancer therapy. Drug Discov Today. 2022;27(9):2526–2540. doi:10.1016/j.drudis.2022.06.007
   PubMed Web of Science ®Google Scholar
• Sun S, Shang E, Ju A, et al. Tumor-targeted hyaluronic acid-mPEG modified nanostructured lipid carriers for cantharidin delivery: an in vivo and in vitro study. Fitoterapia. 2021;155:105033. doi:10.1016/j.fitote.2021.105033
   PubMed Web of Science ®Google Scholar
• Kebebe D, Wu Y, Zhang B, et al. Dimeric c(RGD) peptide conjugated nanostructured lipid carriers for efficient delivery of Gambogic acid to breast cancer. Int J Nanomedicine. 2019;14:6179–6195. doi:10.2147/IJN.S202424
   PubMed Web of Science ®Google Scholar
• Wang Y, Hu W, Ding B, et al. cRGD mediated redox and pH dual responsive poly(amidoamine) dendrimer-poly(ethylene glycol) conjugates for efficiently intracellular antitumor drug delivery. Colloids Surf B Biointerfaces. 2020;194:111195. doi:10.1016/j.colsurfb.2020.111195
   PubMed Web of Science ®Google Scholar
• Liu J, Wu M, Pan Y, et al. Biodegradable nanoscale coordination polymers for targeted tumor combination therapy with oxidative stress amplification. Adv Funct Mat. 2020;30(13):1908865.
   Web of Science ®Google Scholar
• Deepak P, Kumar P, Arya DK, et al. PS. C (RGDfK) anchored surface manipulated liposome for tumor-targeted Tyrosine Kinase Inhibitor (TKI) delivery to potentiate liver anticancer activity. Int J Pharm. 2023 Jun 26:123160
   Google Scholar
• Emami J, Rezazadeh M, Varshosaz J, et al. Formulation of LDL targeted nanostructured lipid carriers loaded with paclitaxel: a detailed study of preparation, freeze drying condition, and in vitro cytotoxicity. J Nanomater. 2012;2012:358782. doi:10.1155/2012/358782
   Web of Science ®Google Scholar
• Emami J, Yousefian H, Sadeghi H. Targeted nanostructured lipid carrier for brain delivery of artemisinin: design, preparation, characterization, optimization and cell toxicity. J Pharm Pharm Sci. 2018;21(1s):225s–241s. doi:10.18433/jpps30117
   PubMedGoogle Scholar
• Sharma M, Mehta I. Surface stabilized atorvastatin nanocrystals with improved bioavailability, safety and antihyperlipidemic potential. Sci Rep. 2019;9(1):16105. doi:10.1038/s41598-019-52645-0
   PubMed Web of Science ®Google Scholar
• Huang R, Li J, Kebebe D, et al. Cell penetrating peptides functionalized gambogic acid-nanostructured lipid carrier for cancer treatment. Drug Deliv. 2018;25(1):757–765. doi:10.1080/10717544.2018.1446474
   PubMed Web of Science ®Google Scholar
• Managuli RS, Wang JT-W, Faruqu FM, et al. Surface engineered nanoliposomal platform for selective lymphatic uptake of asenapine maleate: in vitro and in vivo studies. Mater Sci Eng. 2020;109:110620. doi:10.1016/j.msec.2019.110620
   Google Scholar
• Parashar P, Rathor M, Dwivedi M, et al. Hyaluronic acid decorated naringenin nanoparticles: appraisal of chemopreventive and curative potential for lung cancer. Pharmaceutics. 2018;10(1):33. doi:10.3390/pharmaceutics10010033
   PubMed Web of Science ®Google Scholar
• Jagwani S, Jalalpure S, Dhamecha D, et al. Pharmacokinetic and pharmacodynamic evaluation of resveratrol loaded cationic liposomes for targeting hepatocellular carcinoma. ACS Biomat Sci Eng. 2020;6(9):4969–4984. doi:10.1021/acsbiomaterials.0c00429
   PubMed Web of Science ®Google Scholar
• Zhou Q, Fu Z. In vitro and in vivo study of a novel liposome-mediated dual drug delivery for synergistic lung cancer therapy via oral administration. Onco Targets Ther. 2020;13:12695–12703. doi:10.2147/OTT.S276837
   PubMed Web of Science ®Google Scholar
• Jadhav K, Deore S, Dhamecha D, et al. Phytosynthesis of silver nanoparticles: characterization, biocompatibility studies, and anticancer activity. ACS Biomater Sci Eng. 2018;4(3):892–899. doi:10.1021/acsbiomaterials.7b00707
   PubMed Web of Science ®Google Scholar
• Kesharwani P, Md S, Alhakamy NA, et al. QbD enabled azacitidine loaded liposomal nanoformulation and its in vitro evaluation. Polymers. 2021;13(2):250. doi:10.3390/polym13020250
   PubMed Web of Science ®Google Scholar
• Kesharwani P, Tekade RK, Gajbhiye V, et al. Cancer targeting potential of some ligand-anchored poly(propylene imine) dendrimers: a comparison. Nanomedicine. 2011;7(3):295–304. doi:10.1016/j.nano.2010.10.010
   PubMed Web of Science ®Google Scholar
• Li Y, Tan X, Liu X, et al. Enhanced anticancer effect of doxorubicin by TPGS-coated liposomes with Bcl-2 siRNA-Corona for dual suppression of drug resistance. Asian J Pharm Sci. 2020;15(5):646–660. doi:10.1016/j.ajps.2019.10.003
   PubMed Web of Science ®Google Scholar
• Yugui F, Wang H, Sun D, et al. Nasopharyngeal cancer combination chemoradiation therapy based on folic acid modified, gefitinib and yttrium 90 co-loaded, core-shell structured lipid-polymer hybrid nanoparticles. Biomed Pharmacother. 2019;114:108820. doi:10.1016/j.biopha.2019.108820
   PubMed Web of Science ®Google Scholar
• Chen L-J, Yang C-X, Yan X-P. Liposome-coated persistent luminescence nanoparticles as luminescence trackable drug carrier for chemotherapy. Anal Chem. 2017;89(13):6936–6939. doi:10.1021/acs.analchem.7b01397
   PubMed Web of Science ®Google Scholar
• Kumar P, Agarwal A, Singh AK, et al. Antineoplastic properties of zafirlukast against hepatocellular carcinoma via activation of mitochondrial mediated apoptosis. Regul Toxicol Pharmacol. 2019;109:104489. doi:10.1016/j.yrtph.2019.104489
   PubMed Web of Science ®Google Scholar
• Kumar V, Bhatt P, Rahman M, et al. Fabrication, optimization, and characterization of umbelliferone β-D-galactopyranoside-loaded PLGA nanoparticles in treatment of hepatocellular carcinoma: in vitro and in vivo studies. Int J Nanomedicine. 2017;12:6747–6758. doi:10.2147/IJN.S136629
   PubMed Web of Science ®Google Scholar
• Pandey P, Rahman M, Bhatt PC, et al. Implication of nano-antioxidant therapy for treatment of hepatocellular carcinoma using PLGA nanoparticles of rutin. Nanomedicine. 2018;13(8):849–870. doi:10.2217/nnm-2017-0306
   PubMed Web of Science ®Google Scholar
• Andalib S, Varshosaz J, Hassanzadeh F, et al. Optimization of LDL targeted nanostructured lipid carriers of 5-FU by a full factorial design. Adv Biomed Res. 2012;1(1):45. doi:10.4103/2277-9175.100147
   PubMedGoogle Scholar
• Dewangan HK. Optimization, Evaluation and Delivery of Genistein Loaded Long Circulating Nanostructured Lipid Carriers for Treatment of Cancer Melanoma Cells. Research Square; 2022.
   Google Scholar
• Agrawal M, Saraf S, Pradhan M, et al. Design and optimization of curcumin loaded nano lipid carrier system using Box-Behnken design. Biomed Pharmacother. 2021;141:111919. doi:10.1016/j.biopha.2021.111919
   PubMed Web of Science ®Google Scholar
• Qadir A, Aqil M, Ali A, et al. Nanostructured lipidic carriers for dual drug delivery in the management of psoriasis: systematic optimization, dermatokinetic and preclinical evaluation. J Drug Deliv Sci Technol. 2020;57:101775. doi:10.1016/j.jddst.2020.101775
   Web of Science ®Google Scholar
• Rahman M, Al-Ghamdi SA, Alharbi KS, et al. Ganoderic acid loaded nano-lipidic carriers improvise treatment of hepatocellular carcinoma. Drug Deliv. 2019;26(1):782–793. doi:10.1080/10717544.2019.1606865
   PubMed Web of Science ®Google Scholar
• Li X, Wang J, Li S, et al. Development and evaluation of multifunctional poly(Lactic-co-glycolic acid) nanoparticles embedded in carboxymethyl β-glucan porous microcapsules as a novel drug delivery system for gefitinib. Pharmaceutics. 2019;11(9):469. doi:10.3390/pharmaceutics11090469
   PubMed Web of Science ®Google Scholar
• Jiao J, Wu H, Chen F, et al. Delivery of coumarin-containing all- trans retinoic acid derivatives via targeted nanoparticles encapsulating indocyanine green for chemo/photothermal/photodynamic therapy of breast cancer. New J Chem. 2018;42(11):8805–8814. doi:10.1039/C8NJ00578H
   Web of Science ®Google Scholar
• Phillip Lee YH, Sathigari S, Jean Lin Y-J, et al. Gefitinib–cyclodextrin inclusion complexes: physico-chemical characterization and dissolution studies. Drug Dev Ind Pharm. 2009;35(9):1113–1120. doi:10.1080/03639040902783074
   PubMed Web of Science ®Google Scholar
• Chen W, Di Carlo C, Devery D, et al. Fabrication and characterization of gefitinib-releasing polyurethane foam as a coating for drug-eluting stent in the treatment of bronchotracheal cancer. Int J Pharm. 2018;548(2):803–811. doi:10.1016/j.ijpharm.2017.10.026
   PubMedGoogle Scholar
• Makeen HA, Mohan S, Al-Kasim MA, et al. Gefitinib loaded nanostructured lipid carriers: characterization, evaluation and anti-human colon cancer activity in vitro. Drug Deliv. 2020;27(1):622–631. doi:10.1080/10717544.2020.1754526
   PubMed Web of Science ®Google Scholar
• Wu H, Li N, Jin R, et al. Cytokine levels contribute to the pathogenesis of minimal hepatic encephalopathy in patients with hepatocellular carcinoma via STAT3 activation. Sci Rep. 2016;6(1):18528. doi:10.1038/srep18528
   PubMedGoogle Scholar
• Avrutsky MI, Troy CM. Caspase-9: a multimodal therapeutic target with diverse cellular expression in human disease. 2021;12.
   Google Scholar
• Keshari AK, Singh AK, Kumar U, et al. 5H-benzo[h]thiazolo[2,3-b]quinazolines ameliorate NDEA-induced hepatocellular carcinogenesis in rats through IL-6 downregulation along with oxidative and metabolic stress reduction. Drug Des Devel Ther. 2017;11:2981–2995. doi:10.2147/DDDT.S143075
   PubMed Web of Science ®Google Scholar